Can Serve Free LLC offers specialized investment advisory expertise to Clients who desire to understand oncology financial market dynamics and wisely build investment portfolios comprised of company stocks that fight Lung Cancer.
The Lung Cancer Therapeutics Market Size was valued at USD 18.25 billion in 2023 and is projected to grow from USD 20.05 billion in 2024 to USD 40.60 billion by 2032, exhibiting a compound annual growth rate compound annual growth rate (CAGR) of 8.15% during the forecast period (2024 - 2032).
Lung cancer is one of the most common types of metastatic cancers globally. It begins as a malignant tumor that starts in the lung tissue and spreads to other parts of the body through the bloodstream or lymphatic system. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the most common types of lung cancer. NSCLC is the most common type of lung cancer and accounts for approximately 85% of all lung cancer cases. It has several subtypes which include adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
Lung cancer therapeutics market growth is anticipated because of governments' increasing efforts and investments to build healthcare infrastructure and provide high-quality treatment options. The lung cancer therapeutics market segments include targeted therapy, hormonal therapy, and chemotherapy.
For additional information on Lung Cancer, please review the video by Medical Centric.